# DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer

Source: https://onco.cc/trials/nct05680922/  
OnCo record `nct05680922` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of LB2102 in extensive-stage small-cell lung cancer and large cell neuroendocrine carcinoma of the lung, run by Legend Biotech USA Inc, active but no longer recruiting.

## Summary

DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer is a phase 1 interventional study registered as NCT05680922 by Legend Biotech USA Inc; 41 participants are planned, it started on 2023-07-26; the registry gives 2027-12 as its primary completion date. Interventions recorded: LB2102. Conditions listed: Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05680922
- Phase: 1
- Setting: A First in Human Dose Escalation and Cohort Expansion Study of DLL3-directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
- Sponsor: Legend Biotech USA Inc
- Enrolled: 41

## Sources

- ClinicalTrials.gov NCT05680922: https://clinicaltrials.gov/study/NCT05680922

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [LB2102](https://onco.cc/drugs/lb2102/)
- companies: [Legend Biotech](https://onco.cc/companies/legend-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05680922.json